Royalty Pharma officer proposes $502K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc (RPRX) officer Marshall Urist reported a proposed sale of 9,098 shares of common stock, with an approximate sale date of June 24, 2026 and an aggregate market value of $502,066.55. The notice separately records the acquisition of 9,098 Class A ordinary shares from Royalty Pharma plc on May 8, 2026 as an Equity Performance Award under the issuer’s equity compensation program. It lists February 12, 2026 as the Rule 10b5-1 plan adoption or instruction date.
Key Figures
Key Terms
Equity Performance Award financial
Rule 10b5-1 regulatory
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What recent RPRX sales did Marshall Urist report?
AI-generated analysis. How Rhea-AI works. Not financial advice.